Update on immune checkpoint inhibitors in gynecological cancers.
- Author:
Valerie HEONG
1
;
Natalie NGOI
;
David Shao Peng TAN
Author Information
- Publication Type:Review
- Keywords: Neoplasms; Tumor Microenvironment; Immunotherapy; Biomarkers
- MeSH: Biomarkers; CTLA-4 Antigen; Humans; Immunotherapy; Tumor Microenvironment
- From:Journal of Gynecologic Oncology 2017;28(2):e20-
- CountryRepublic of Korea
- Language:English
- Abstract: In recent years, progress in our understanding of immune-modulatory signaling pathways in immune cells and the tumor microenvironment (TME) has led to rejuvenated interest in cancer immunotherapy. In particular, immunotherapy targeting the immune checkpoint receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell-death 1 (PD-1), and programmed cell-death ligand 1 (PD-L1) have demonstrated clinical activity in a wide variety of tumors, including gynecological cancers. This review will focus on the emerging clinical data on the therapeutic role of immune checkpoint inhibitors, and potential strategies to enhance the efficacy of this class of compounds, in the context of gynecological cancers. It is anticipated that future biomarker-directed clinical trials will provide further insights into the mechanisms underlying response and resistance to immunotherapy, and help guide our approach to designing therapeutic combinations that have the potential to enhance the benefit of immunotherapy in patients with gynecologic cancers.
